Stock Analiz

Arcturus Therapeutics Holdings Inc. ARCT

Biotechnology: Pharmaceutical Preparations · IPO 2013 · data as of November 13, 2026

$8.36Market cap $241M
Open the interactive analysis →

Arcturus Therapeutics Holdings Inc. (ARCT) is a healthcare company listed in the US with a market value of about $241M. In the twelve months to September 30, 2026 it had revenue of $31M and net income of -$87M, a net margin of -285.9%.

Its overall Stock Analiz score is 0.8 out of 5 (weak). The strongest part is financial health (2/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 54% a year, a 5-year average ROIC of -26%.

About Arcturus Therapeutics

Arcturus Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2013. Revenue went from $16M in 2018 to $82M in 2025, growth of about 26.6% a year. It was profitable in 1 of the last 8 years in our data. It spends 137% of revenue on research and development.

Score: 0.8 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health2/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • 5-year revenue growth above 8% a year
  • More cash than debt, or low debt to equity
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S7.9
P/B1.4
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-25.9%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-46.1%
Revenue growth (5 yrs, per year)53.8%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-358.9%
ROIC (5-yr avg.)-26.3%
Profitable years (of last 10)1
Years paying a dividend—

Financials, last 8 years

Fiscal yearTTM20252024202320222021202020192018
Revenue$31M$82M$152M$167M$206M$12M$10M$21M$16M
Net income-$87M-$66M-$81M-$30M$9M-$204M-$72M-$26M-$22M
Free cash flow-$63M-$75M-$60M-$21M$24M-$138M-$45M-$7M-$22M
EPS (diluted)$-3.10$-2.40$-3.00$-1.12$0.35$-7.74$-3.55$-2.15$-2.16
Net margin-285.9%-80.2%-53.1%-17.8%4.5%-1648.0%-756.4%-125.0%-138.3%
ROIC—-25.2%-35.5%-20.0%2.9%-53.9%-13.5%-43.0%-73.2%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

What analysts expect

The average 12-month price target from 10 analysts is $23.80, 185% above the current price; targets range from $9.00 to $41.00; the consensus rating is “Strong buy”; expected EPS is $-2.90 for the fiscal year ending December 31, 2026.

Frequently asked questions

Does Arcturus Therapeutics pay a dividend?

Not currently.

Is Arcturus Therapeutics a good stock to buy?

We do not give buy or sell advice. Arcturus Therapeutics scores 0.8 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.